Hacker News Reader

Comment by adamredwoods | Hacker News Reader

For leukemia, there are a lot of promising new treatments and clinical trials. For metastatic solid-state tumors, much less. We're still in the dark ages of cancer treatment.

View on HN

FYI: your comment is a unique result for “metastatic solid-state tumors”[1], so much much less?

[1] https://www.google.co.nz/search?q=%22metastatic+solid-state+...

I think he means just solid in the sense that it’s not moving cells.

I think the usual split of solid tumor vs blood (aka 'hematologic' or 'heme')

The "-state" part is the neologism. GP meant "solid tumors" or "solid cancers".

We talking tumors in the state of metastatic solid?

What treatments in particular?

Car-T seems promising for leukemia and lymphoma, but not as efficacious in solid tumors:

https://www.lls.org/treatment/types-treatment/immunotherapy/...

Also 2nd gen BTK inhibitors:

https://en.wikipedia.org/wiki/Acalabrutinib

https://en.wikipedia.org/wiki/Bruton%27s_tyrosine_kinase

BTK inhibitors are technically in 3rd gen (noncovalent) already if you can get in the trials (which are very promising considering they use the same mechanism).

Imatinib (Gleevac) revolutionized treatment for patients with chronic myeloid leukemia (CML). Prior to the drug’s discovery, CML patients generally had seven years to live (possibly less depending on how advanced the cancer was). Now their lifespan mirrors the general population.

I’d highly recommend the book The Philadelphia Chromosome if you’re interested in learning more.

I am currently taking a similar drug for Myelofibrosis on a clinical trial holed up after a stem cell transplant here at MD Anderson Cancer Center. It's called Itacitinib, and is supposed to prevent GVHD. It's by the same company that makes Jakafi (brand name). These are expensive drugs for sure, and my DR is running the clinical trial. Just wanted to chime in from the inside. ;p

Best of luck for your treatment

Reply on news.ycombinator.com